	US 12,291,573 B2
	Application of a nanobody targeting on IL-6RA
Bofeng Li, Anhui (CN); Tengchuan Jin, Anhui (CN); and Jiaojiao Qian, Anhui (CN)
Assigned to INSTITUTE OF HEALTH AND MEDICINE, HEFEI COMPREHENSIVE NATIONAL SCIENCE CENTER, Anhui (CN)
Filed by INSTITUTE OF HEALTH AND MEDICINE, HEFEI COMPREHENSIVE NATIONAL SCIENCE CENTER, Anhui (CN)
Filed on Apr. 22, 2024, as Appl. No. 18/642,478.
Application 18/642,478 is a continuation of application No. PCT/CN2023/124570, filed on Oct. 13, 2023.
Claims priority of application No. 202211342568.2 (CN), filed on Oct. 31, 2022.
Prior Publication US 2024/0343816 A1, Oct. 17, 2024
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 1/16 (2006.01)

CPC C07K 16/2866 (2013.01) [A61P 1/16 (2018.01); A61K 2039/505 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/76 (2013.01)]

13 Claims

1. A nanobody targeting an IL-6Rα protein, wherein the nanobody comprises a heavy chain variable region comprising CDR1 of SEQ ID NO.2, CDR2 of SEQ ID NO.3, and CDR3 of SEQ ID NO.4.